MicroRNA profiling in human breast cancer cell lines exposed to the anti-neoplastic drug cediranib
- Authors:
- A.L.R. Bordinhão
- A.F. Evangelista
- R.J.S. Oliveira
- T. Macedo
- H.C. Silveira
- R.M. Reis
- M.M. Marques
-
Affiliations: Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, São Paulo, Brazil - Published online on: October 7, 2016 https://doi.org/10.3892/or.2016.5153
- Pages: 3197-3206
This article is mentioned in:
Abstract
 |
 |
 |
 |
 |
 |
 |
 |
|
Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Lønning PE: Molecular basis for therapy resistance. Mol Oncol. 4:284–300. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Arpino G, Green SJ, Allred DC, Lew D, Martino S, Osborne CK and Elledge RM: HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: A southwest oncology group study. Clin Cancer Res. 10:5670–5676. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Wedge SR, Kendrew J, Hennequin LF, Valentine PJ, Barry ST, Brave SR, Smith NR, James NH, Dukes M, Curwen JO, et al: AZD2171: A highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res. 65:4389–4400. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Brave SR, Ratcliffe K, Wilson Z, James NH, Ashton S, Wainwright A, Kendrew J, Dudley P, Broadbent N, Sproat G, et al: Assessing the activity of cediranib, a VEGFR-2/3 tyrosine kinase inhibitor, against VEGFR-1 and members of the structurally related PDGFR family. Mol Cancer Ther. 10:861–873. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Drevs J, Siegert P, Medinger M, Mross K, Strecker R, Zirrgiebel U, Harder J, Blum H, Robertson J, Jürgensmeier JM, et al: Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J Clin Oncol. 25:3045–3054. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Batchelor TT, Duda DG, di Tomaso E, Ancukiewicz M, Plotkin SR, Gerstner E, Eichler AF, Drappatz J, Hochberg FH, Benner T, et al: Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol. 28:2817–2823. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Goss GD, Arnold A, Shepherd FA, Dediu M, Ciuleanu TE, Fenton D, Zukin M, Walde D, Laberge F, Vincent MD, et al: Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study. J Clin Oncol. 28:49–55. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Dahut WL, Madan RA, Karakunnel JJ, Adelberg D, Gulley JL, Turkbey IB, Chau CH, Spencer SD, Mulquin M, Wright J, et al: Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer. BJU Int. 111:1269–1280. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Martinho O, Silva-Oliveira R, Miranda-Gonçalves V, Clara C, Almeida JR, Carvalho AL, Barata JT and Reis RM: In vitro and in vivo analysis of RTK inhibitor efficacy and identification of its novel targets in glioblastomas. Transl Oncol. 6:187–196. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Miller KD, Miller M, Mehrotra S, Agarwal B, Mock BH, Zheng QH, Badve S, Hutchins GD and Sledge GW Jr: A physiologic imaging pilot study of breast cancer treated with AZD2171. Clin Cancer Res. 12:281–288. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Denduluri N, Tan AR, Walshe J, Berman A, Yang SX, Chow CK and Swain SM: A pilot study to evaluate the vascular endothelial growth factor receptor tyrosine kinase inhibitor AZD2171 and chemotherapy in locally advanced and inflammatory breast cancer. Clin Breast Cancer. 6:460–463. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Hyams DM, Chan A, de Oliveira C, Snyder R, Vinholes J, Audeh MW, Alencar VM, Lombard J, Mookerjee B, Xu J, et al: Cediranib in combination with fulvestrant in hormone-sensitive metastatic breast cancer: A randomized Phase II study. Invest New Drugs. 31:1345–1354. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Liu JF, Tolaney SM, Birrer M, Fleming GF, Buss MK, Dahlberg SE, Lee H, Whalen C, Tyburski K, Winer E, et al: A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer. Eur J Cancer. 49:2972–2978. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Sahebjam S, Bedard PL, Castonguay V, Chen Z, Reedijk M, Liu G, Cohen B, Zhang WJ, Clarke B, Zhang T, et al: A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503). Br J Cancer. 109:943–949. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Almeida MI, Reis RM and Calin GA: MicroRNA history: Discovery, recent applications, and next frontiers. Mutat Res. 717:1–8. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M, et al: Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA. 101:2999–3004. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang B, Pan X, Cobb GP and Anderson TA: microRNAs as oncogenes and tumor suppressors. Dev Biol. 302:1–12. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Garzon R, Marcucci G and Croce CM: Targeting microRNAs in cancer: Rationale, strategies and challenges. Nat Rev Drug Discov. 9:775–789. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Harquail J, Benzina S and Robichaud GA: MicroRNAs and breast cancer malignancy: An overview of miRNA-regulated cancer processes leading to metastasis. Cancer Biomark. 11:269–280. 2012.PubMed/NCBI | |
|
Singh R and Mo YY: Role of microRNAs in breast cancer. Cancer Biol Ther. 14:201–212. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Valastyan S: Roles of microRNAs and other non-coding RNAs in breast cancer metastasis. J Mammary Gland Biol Neoplasia. 17:23–32. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Marino ALF, Evangelista AF, Vieira RAC, Macedo T, Kerr LM, Abrahão-Machado LF, Longatto-Filho A, Silveira HC and Marques MM: MicroRNA expression as risk biomarker of breast cancer metastasis: A pilot retrospective case-cohort study. BMC Cancer. 14:7392014. View Article : Google Scholar : PubMed/NCBI | |
|
Wiemer EAC: Role of microRNAs in anti-cancer drug resistanceMicroRNAs in Cancer Translational Research. Cho WCS: Springer; Netherlands: pp. 449–483. 2011, http://link.springer.com/chapter/10.1007/978-94-007-0298-1_19Accessed November 20, 2013. View Article : Google Scholar | |
|
Kastl L, Brown I and Schofield AC: miRNA-34a is associated with docetaxel resistance in human breast cancer cells. Breast Cancer Res Treat. 131:445–454. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Climent J, Dimitrow P, Fridlyand J, Palacios J, Siebert R, Albertson DG, Gray JW, Pinkel D, Lluch A and Martinez-Climent JA: Deletion of chromosome 11q predicts response to anthracycline-based chemotherapy in early breast cancer. Cancer Res. 67:818–826. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Zhu H, Wu H, Liu X, Evans BR, Medina DJ, Liu CG and Yang JM: Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells. Biochem Pharmacol. 76:582–588. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Kovalchuk O, Filkowski J, Meservy J, Ilnytskyy Y, Tryndyak VP, Chekhun VF and Pogribny IP: Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol Cancer Ther. 7:2152–2159. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Liang Z, Wu H, Xia J, Li Y, Zhang Y, Huang K, Wagar N, Yoon Y, Cho HT, Scala S, et al: Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. Biochem Pharmacol. 79:817–824. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Andorfer CA, Necela BM, Thompson EA and Perez EA: MicroRNA signatures: Clinical biomarkers for the diagnosis and treatment of breast cancer. Trends Mol Med. 17:313–319. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Mahadevan D, Cooke L, Riley C, Swart R, Simons B, Della Croce K, Wisner L, Iorio M, Shakalya K, Garewal H, et al: A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors. Oncogene. 26:3909–3919. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Weiss GJ, Bemis LT, Nakajima E, Sugita M, Birks DK, Robinson WA, Varella-Garcia M, Bunn PA Jr, Haney J, Helfrich BA, et al: EGFR regulation by microRNA in lung cancer: Correlation with clinical response and survival to gefitinib and EGFR expression in cell lines. Ann Oncol. 19:1053–1059. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Dirks WG, Faehnrich S, Estella IAJ and Drexler HG: Short tandem repeat DNA typing provides an international reference standard for authentication of human cell lines. ALTEX. 22:103–109. 2005.PubMed/NCBI | |
|
drc R Package. http://cran.r-project.org/web/packages/drc/ | |
|
The R project for statistical computing. http://www.r-project.org | |
|
Pinto F, Pértega-Gomes N, Pereira MS, Vizcaíno JR, Monteiro P, Henrique RM, Baltazar F, Andrade RP and Reis RM: T-box transcription factor brachyury is associated with prostate cancer progression and aggressiveness. Clin Cancer Res. 20:4949–4961. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Martinho O, Zucca LE and Reis RM: AXL as a modulator of sunitinib response in glioblastoma cell lines. Exp Cell Res. 332:1–10. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Viana CR, Neto CS, Kerr LM, Palmero EI, Marques MMC, Colaiacovo T, de Queiroz Junior AF, Carvalho AL and Siqueira SA: The interference of cold ischemia time in the quality of total RNA from frozen tumor samples. Cell Tissue Bank. 14:167–173. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Macedo C, Evangelista AF, Marques MM, Octacílio-Silva S, Donadi EA, Sakamoto-Hojo ET and Passos GA: Autoimmune regulator (Aire) controls the expression of microRNAs in medullary thymic epithelial cells. Immunobiology. 218:554–560. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Aroma-light. http://www.bioconductor.org/packages/2.12/bioc/html/aroma.light.html | |
|
Hong F, Breitling R, McEntee CW, Wittner BS, Nemhauser JL and Chory J: RankProd: A bioconductor package for detecting differentially expressed genes in meta-analysis. Bioinformatics. 22:2825–2827. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
gplots: Various R programming tools for plotting data. http://cran.r-project.org/web/packages/gplots/index.html | |
|
mirDIP: microRNA data integration portal. http://ophid.utoronto.ca/mirDIP/ | |
|
Bioinformatics Resouces DAVID: 6.7. http://david.abcc.ncifcrf.gov | |
|
Supek F, Bošnjak M, Škunca N and Šmuc T: REVIGO summarizes and visualizes long lists of gene ontology terms. PLoS One. 6:e218002011. View Article : Google Scholar : PubMed/NCBI | |
|
Pfaffl MW: A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 29:e452001. View Article : Google Scholar : PubMed/NCBI | |
|
Andersen CL, Jensen JL and Ørntoft TF: Normalization of real-time quantitative reverse transcription-PCR data: A model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Res. 64:5245–5250. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Lindahl T, Satoh MS, Poirier GG and Klungland A: Post-translational modification of poly(ADP-ribose) polymerase induced by DNA strand breaks. Trends Biochem Sci. 20:405–411. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Downward J: Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer. 3:11–22. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Tao LY, Liang YJ, Wang F, Chen LM, Yan YY, Dai CL and Fu LW: Cediranib (recentin, AZD2171) reverses ABCB1- and ABCC1-mediated multidrug resistance by inhibition of their transport function. Cancer Chemother Pharmacol. 64:961–969. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Tetsu O, Phuchareon J, Eisele DW, Hangauer MJ and McCormick F: AKT inactivation causes persistent drug tolerance to EGFR inhibitors. Pharmacol Res. 102:132–137. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Ford CE, Ma SS Qian, Quadir A and Ward RL: The dual role of the novel Wnt receptor tyrosine kinase, ROR2, in human carcinogenesis. Int J Cancer. 133:779–787. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Henry C, Quadir A, Hawkins NJ, Jary E, Llamosas E, Kumar D, Daniels B, Ward RL and Ford CE: Expression of the novel Wnt receptor ROR2 is increased in breast cancer and may regulate both β-catenin dependent and independent Wnt signalling. J Cancer Res Clin Oncol. 141:243–254. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Malavaki CJ, Roussidis AE, Gialeli C, Kletsas D, Tsegenidis T, Theocharis AD, Tzanakakis GN and Karamanos NK: Imatinib as a key inhibitor of the platelet-derived growth factor receptor mediated expression of cell surface heparan sulfate proteoglycans and functional properties of breast cancer cells. FEBS J. 280:2477–2489. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Thanigaimani S, Kichenadasse G and Mangoni AA: The emerging role of vascular endothelial growth factor (VEGF) in vascular homeostasis: Lessons from recent trials with anti-VEGF drugs. Curr Vasc Pharmacol. 9:358–380. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou M, Liu Z, Zhao Y, Ding Y, Liu H, Xi Y, Xiong W, Li G, Lu J, Fodstad O, et al: MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression. J Biol Chem. 285:21496–21507. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Nordentoft I, Birkenkamp-Demtroder K, Agerbæk M, Theodorescu D, Ostenfeld MS, Hartmann A, Borre M, Ørntoft TF and Dyrskjøt L: miRNAs associated with chemo-sensitivity in cell lines and in advanced bladder cancer. BMC Med Genomics. 5:402012. View Article : Google Scholar : PubMed/NCBI | |
|
Yin W, Wang P, Wang X, Song W, Cui X, Yu H and Zhu W: Identification of microRNAs and mRNAs associated with multidrug resistance of human laryngeal cancer Hep-2 cells. Braz J Med Biol Res. 46:546–554. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Lee K, Kunkeaw N, Jeon SH, Lee I, Johnson BH, Kang GY, Bang JY, Park HS, Leelayuwat C and Lee YS: Precursor miR-886, a novel noncoding RNA repressed in cancer, associates with PKR and modulates its activity. RNA. 17:1076–1089. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Jeon SH, Lee K, Lee KS, Kunkeaw N, Johnson BH, Holthauzen LMF, Gong B, Leelayuwat C and Lee YS: Characterization of the direct physical interaction of nc886, a cellular non-coding RNA, and PKR. FEBS Lett. 586:3477–3484. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Jeon SH, Johnson BH and Lee YS: A tumor surveillance model: A non-coding RNA senses neoplastic cells and its protein partner signals cell death. Int J Mol Sci. 13:13134–13139. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Cao J, Song Y, Bi N, Shen J, Liu W, Fan J, Sun G, Tong T, He J, Shi Y, et al: DNA methylation-mediated repression of miR-886-3p predicts poor outcome of human small cell lung cancer. Cancer Res. 73:3326–3335. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Xiong Y, Zhang L, Holloway AK, Wu X, Su L and Kebebew E: MiR-886-3p regulates cell proliferation and migration, and is dysregulated in familial non-medullary thyroid cancer. PLoS One. 6:e247172011. View Article : Google Scholar : PubMed/NCBI | |
|
Noonan EJ, Place RF, Basak S, Pookot D and Li LC: miR-449a causes Rb-dependent cell cycle arrest and senescence in prostate cancer cells. Oncotarget. 1:349–358. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Miao LJ, Huang SF, Sun ZT, Gao ZY, Zhang RX, Liu Y and Wang J: MiR-449c targets c-Myc and inhibits NSCLC cell progression. FEBS Lett. 587:1359–1365. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Luo W, Huang B, Li Z, Li H, Sun L, Zhang Q, Qiu X and Wang E: MicroRNA-449a is downregulated in non-small cell lung cancer and inhibits migration and invasion by targeting c-Met. PLoS One. 8:e647592013. View Article : Google Scholar : PubMed/NCBI | |
|
Fang Y, Gu X, Li Z, Xiang J and Chen Z: miR-449b inhibits the proliferation of SW1116 colon cancer stem cells through downregulation of CCND1 and E2F3 expression. Oncol Rep. 30:399–406. 2013.PubMed/NCBI | |
|
Bou Kheir T, Futoma-Kazmierczak E, Jacobsen A, Krogh A, Bardram L, Hother C, Grønbæk K, Federspiel B, Lund AH and Friis-Hansen L: miR-449 inhibits cell proliferation and is down-regulated in gastric cancer. Mol Cancer. 10:292011. View Article : Google Scholar : PubMed/NCBI | |
|
Feng M and Yu Q: miR-449 regulates CDK-Rb-E2F1 through an auto-regulatory feedback circuit. Cell Cycle. 9:213–214. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Yan F, Liu H, Hao J and Liu Z: Dynamical behaviors of Rb-E2F pathway including negative feedback loops involving miR449. PLoS One. 7:e439082012. View Article : Google Scholar : PubMed/NCBI | |
|
Yang X, Feng M, Jiang X, Wu Z, Li Z, Aau M and Yu Q: miR-449a and miR-449b are direct transcriptional targets of E2F1 and negatively regulate pRb-E2F1 activity through a feedback loop by targeting CDK6 and CDC25A. Genes Dev. 23:2388–2393. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou X, Ren Y, Moore L, Mei M, You Y, Xu P, Wang B, Wang G, Jia Z, Pu P, et al: Downregulation of miR-21 inhibits EGFR pathway and suppresses the growth of human glioblastoma cells independent of PTEN status. Lab Invest. 90:144–155. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Cho WCS, Chow ASC and Au JSK: MiR-145 inhibits cell proliferation of human lung adenocarcinoma by targeting EGFR and NUDT1. RNA Biol. 8:125–131. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Zhu H, Dougherty U, Robinson V, Mustafi R, Pekow J, Kupfer S, Li YC, Hart J, Goss K, Fichera A, et al: EGFR signals downregulate tumor suppressors miR-143 and miR-145 in Western diet-promoted murine colon cancer: Role of G1 regulators. Mol Cancer Res. 9:960–975. 2011. View Article : Google Scholar : PubMed/NCBI |
